Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
Zsuzsanna H McMahanCarol ZhaoRajan SaggarStephen C MathaiLorinda ChungJ Gerry CoghlanMehul ShahJohn HartneyVallerie McLaughlinPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Modern therapy provides a similar reduction in morbidity/mortality risk in patients with CTD-PAH when compared to the PAH population overall. Risk of death is higher in CTD-PAH patients than in those with PAH overall, but survival has improved in the last 10 years, which may be related to increased screening and/or new treatment approaches. Early detection of PAH in patients with CTD and up-front intensive treatment are warranted.
Keyphrases
- pulmonary arterial hypertension
- end stage renal disease
- polycyclic aromatic hydrocarbons
- chronic kidney disease
- pulmonary artery
- randomized controlled trial
- stem cells
- ejection fraction
- meta analyses
- peritoneal dialysis
- newly diagnosed
- mesenchymal stem cells
- coronary artery
- replacement therapy
- bone marrow
- cross sectional